ProNAi Therapeutics, Inc. (DNAI)
(Delayed Data from NSDQ)
$1.56 USD
-0.07 (-4.29%)
Updated Jan 9, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[DNAI]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Lowering PT to $3; PNT2258 Development Suspended Due to Low Response Rates in Wolverine
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
DNAI Expands Pipeline with Licensing of Cdc7 Inhibitor AS-141, Reiterate OUTPERFORM and $36 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Q1 EPS; Interim Wolverine Data Ahead at ASCO, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 11
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Q4:15 EPS; Wolverine Data in DLBCL on Track for ASCO,Richter''s Data YE:16, Reiterate OUTPERFORM and $36 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
After a Rough Start, Opportunities Begin to Stand Out
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Biotech Year-End Review, What to Expect in 2016
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Q3:15 Results; Looking Ahead to Data and Further Ph 2 Initiations in 2016, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Q3:15 Results; Looking Ahead to Data and Further Ph 2 Initiations in 2016, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
DNAI Initiates Study of PNT2258 in Richter''s patients, Setting up Busy 2016. Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Q2:EPS; Preparing to Initiate Registration-Focused Richter''s Transformed CLL Trial, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Initiating with OUTPERFORM and $36 Price Target; DNAi - Turning off Oncogenes at the Source
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
|